The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Improving bioavailability using predictive modeling for solubility enhancement
Improving exposure for a low-solubility compound
Low solubility can limit systemic exposure, increasing the risk of unpredictable outcomes and creating a barrier to clinical progression.
Case study overview
In this case study, predictive modeling with the OSDPredict™ platform was used to prioritize optimal formulation strategies for a program facing low-solubility challenges. This approach improved exposure and supported accelerated advancement toward Phase I clinical trials.
Using the OSDPredict™ platform, scientists were able to:
- Assess solubility limitations and their impact on bioavailability
- Predict in vivo exposure across different formulation approaches
- Prioritize optimal formulation strategies earlier in development
- Enable more informed decision-making before clinical studies
Key outcomes of an optimized HPMCAS-M formulation
- Improved systemic exposure for a poorly soluble compound
- Accelerated progression toward Phase I clinical studies
- Reduced formulation risk through data-driven strategy selection
- Increased confidence in candidate viability for clinical trials
